Opioid peptides and primary biliary cirrhosis

Clonidine blocks acute opiate-withdrawal symptoms

Gold, M., Redmond, D. E., & Kleber, H. (1978) · The Lancet · doi:10.1016/s0140-6736(78)92823-4 · Cited by 710 · see citing works

Dynorphin1–8 and dynorphin1–9 are ligands for the κ-subtype of opiate receptor

Corbett, A. D., Paterson, S. J., McKnight, A. T., Magnan, J., & Kosterlitz, H. W. (1982) · Nature · doi:10.1038/299079a0 · Cited by 447 · see citing works

Serum bilirubin: a prognostic factor in primary biliary cirrhosis

Shapiro, J. M., Smith, H., & Schaffner, F. (1979) · Gut · doi:10.1136/gut.20.2.137 · Cited by 319 · see citing works

Entry of Opioid Peptides into the Central Nervous System

Рапопорт, С. И., Klee, W. A., Pettigrew, K. D., & Ohno, K. (1980) · Science · doi:10.1126/science.7350645 · Cited by 245 · see citing works

Blood-Brain Barrier Restriction of Peptides and the Low Uptake of Enkephalins*

Cornford, E. M., Braun, L. D., Crane, P. D., & Oldendorf, W. H. (1978) · Endocrinology · doi:10.1210/endo-103-4-1297 · Cited by 220 · see citing works

Physical Dependence of Opiate-Like Peptides

Wei, E. T., & Loh, H. H. (1976) · Science · doi:10.1126/science.986687 · Cited by 219 · see citing works

Induction of human cutaneous mast cell degranulation by opiates and endogenous opioid peptides: Evidence for opiate and nonopiate receptor participation

Casale, T. B., Bowman, S., & Kaliner, M. (1984) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(84)90447-0 · Cited by 202 · see citing works

The combined use of clonidine and naltrexone as a rapid, safe, and effective treatment of abrupt withdrawal from methadone

Charney, D. S., Heninger, G. R., & Kleber, H. D. (1986) · American Journal of Psychiatry · doi:10.1176/ajp.143.7.831 · Cited by 121 · see citing works

Transport of Leucine‐Enkephalin Across the Blood‐Brain Barrier in the Perfused Guinea Pig Brain

Zloković, B. V., Lipovac, M. N., Begley, D. J., Davson, H., & Rakić, L. (1987) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1987.tb03431.x · Cited by 118 · see citing works

Carrier-mediated transport of enkephalins and N-Tyr-MIF-1 across blood-brain barrier

Banks, W. A., Kastin, A. J., Fischman, A. J., Coy, D. H., & Strauss, S. L. (1986) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1986.251.4.e477 · Cited by 115 · see citing works

Clonidine for opiate detoxification: outpatient clinical trials

Washton, A. M., & Resnick, R. B. (1980) · American Journal of Psychiatry · doi:10.1176/ajp.137.9.1121 · Cited by 108 · see citing works

Binding of a new opiate antagonist, nalmefene, to rat brain membranes.

Me, M., Bolger, G. T., & Weissman, B. A. (1985) · PubMed · Cited by 106 · see citing works

Nalmefene: Intravenous safety and kinetics of a new opioid antagonist

Dixon, R., Howes, J. F., Gentile, J., Hsu, H., Hsiao, J. H., Garg, D. C., Weidler, D. J., Meyer, M. C., & Tuttle, R. R. (1986) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1986.9 · Cited by 98 · see citing works

Blood-brain barrier, half-time disappearance, and brain distribution for labeled enkephalin and a potent analog

Kastin, A. J., Nissen, C., Schally, A. V., et al. (1976) · Brain Research Bulletin · doi:10.1016/0361-9230(76)90085-x · Cited by 95 · see citing works

Hemodynamic effects of a clonidine-induced decrease in sympathetic tone in patients with cirrhosis

Moreau, R., Lee, S. S., Hadengue, A., et al. (1987) · Hepatology · doi:10.1002/hep.1840070129 · Cited by 95 · see citing works

Naloxone‐precipitated withdrawal: A method for rapid induction onto naltrexone

Resnick, R. B., Kestenbaum, R. S., Washton, A. M., et al. (1977) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1977214409 · Cited by 94 · see citing works

SYMPATHETIC TONE MODULATES PORTAL VENOUS PRESSURE IN ALCOHOLIC CIRRHOSIS

Willett, I. R., Jennings, G., Esler, M., & Dudley, F. J. (1986) · The Lancet · doi:10.1016/s0140-6736(86)90599-4 · Cited by 88 · see citing works

STUDIES OF THE OPIATE CONTROL OF PROLACTIN, GH AND TSH

Grossman, A. B., STUBBS, W. A., Gaillard, R.-C., Delitala, G., REES, L. H., & BESSER, G. M. (1981) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1981.tb00624.x · Cited by 79 · see citing works

Prolonged blockade of opioid effect with oral nalmefene

Gal, T. J., DiFazio, C. A., & Dixon, R. (1986) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1986.220 · Cited by 67 · see citing works

Plasma methionine enkephalin concentration and prognosis in primary biliary cirrhosis.

Thornton, J. R., & Losowsky, M. S. (1988) · BMJ · doi:10.1136/bmj.297.6658.1241 · Cited by 66 · see citing works

Reaction of Opioid Peptides with Neutral Endopeptidase (‘Enkephalinase”)

Hersh, L. B. (1984) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1984.tb00925.x · Cited by 61 · see citing works

Endogenous opioids and related peptides: from molecular biology to clinical medicine The Sir Henry Dale Lecture for 1985

Imura, H., Kato, Y., Nakai, Y., Nakao, K., Tanaka, I., Jingami, H., Koh, T., Yoshimasa, T., Tsukada, T., Suda, M., et al. (1985) · Journal of Endocrinology · doi:10.1677/joe.0.1070147 · Cited by 59 · see citing works

The influence of endorphins on peritoneal and mucosal mast cell secretion

Shanahan, F., Lee, T. D. G., Bienenstock, J., et al. (1984) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(84)90385-3 · Cited by 56 · see citing works

Methionine enkephalin is increased in plasma in acute liver disease and is present in bile and urine

Thornton, S. R., & Losowsky, M. S. (1989) · Journal of Hepatology · doi:10.1016/0168-8278(89)90161-x · Cited by 51 · see citing works

Plasma leucine enkephalin is increased in liver disease.

Thornton, J. R., & Losowsky, M. S. (1989) · Gut · doi:10.1136/gut.30.10.1392 · Cited by 44 · see citing works

Is ascites caused by impaired hepatic inactivation of blood borne endogenous opioid peptides?

Thornton, J. R., Dean, H. G., & Losowsky, M. S. (1988) · Gut · doi:10.1136/gut.29.9.1167 · Cited by 44 · see citing works

IgE-mediated 14C-serotonin release from rat mast cells modulated by morphine and endorphins

Yamasaki, Y., SHIMAMURA, O., Kizu, A., et al. (1982) · Life Sciences · doi:10.1016/0024-3205(82)90333-2 · Cited by 36 · see citing works

Histamine Release Induced by Dynorphin-(1-13) from Rat Mast Cells

Sugiyama, K., & Furuta, H. (1984) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.35.247 · Cited by 31 · see citing works

Kappa receptor mediated opioid dependence in rhesus monkeys

Gmerek, D. E., & Woods, J. H. (1986) · Life Sciences · doi:10.1016/0024-3205(86)90287-0 · Cited by 25 · see citing works

Clonidine blocks acute opiate-withdrawal symptoms

(1979) · Journal of the American College of Emergency Physicians · doi:10.1016/s0361-1124(79)80386-x · Cited by 20 · see citing works

A Role for the Kidneys and Liver in Plasma Beta-Endorphin Elimination?

Thornton, J. R., & Losowsky, M. S. (1988) · Clinical Science · doi:10.1042/cs074051pa · Cited by 5 · see citing works

Primary biliary cirrhosis # †

Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099 · see citing works

Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases

Lindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913 · see citing works

Oral naltrexone treatment for cholestatic pruritus: A double-blind, placebo-controlled study

Wolfhagen, F., Sternieri, E., Hop, W., Vitale, G., Bertolotti, M., & Van Buuren, H. (1997) · Gastroenterology · doi:10.1053/gast.1997.v113.pm9322521 · Cited by 343 · see citing works

The Pruritus of Cholestasis

Jones, A. E., & Bergasa, N. V. (1999) · Hepatology · doi:10.1002/hep.510290450 · Cited by 202 · see citing works

Open‐label trial of oral nalmefene therapy for the pruritus of cholestasis

Bergasa, N. V., Schmitt, J. M., Talbot, T. L., Alling, D. W., Swain, M. G., Turner, M. L., Jenkins, J. B., & Jones, A. E. (1998) · Hepatology · doi:10.1002/hep.510270307 · Cited by 182 · see citing works

The efficacy and safety of bile acid binding agents, opioid antagonists or rifampin in the treatment of cholestasis-associated pruritus

Tandon, P., Rowe, B. H., Vandermeer, B., & Bain, V. G. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01200.x · Cited by 176 · see citing works

Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials

Khurana, S., & Singh, P. (2006) · Liver International · doi:10.1111/j.1478-3231.2006.01326.x · Cited by 162 · see citing works

Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: A controlled study

Bergasa, N. V., Alling, D. W., Talbot, T. L., Wells, M. C., & Jones, E. A. (1999) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(99)70117-9 · Cited by 163 · see citing works

Effect of oral naltrexone on pruritus in cholestatic patients

Mansour-Ghanaei, F. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i7.1125 · Cited by 89 · see citing works

Florid opioid withdrawal-like reaction precipitated by naltrexone in a patient with chronic cholestasis

Jones, E. A., & Dekker, L. R. C. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70225-3 · Cited by 78 · see citing works

Pain as a complication of use of opiate antagonists for symptom control in cholestasis

Mcrae, C. A., Prince, M. I., Hudson, M., Day, C. P., James, O. F. W., & Jones, D. E. J. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00879-5 · Cited by 73 · see citing works

Liver transplantation for intractable pruritus is contraindicated before an adequate trial of opiate antagonist therapy

Neuberger, J., & Jones, E. A. (2001) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200111000-00022 · Cited by 60 · see citing works

Nalmefene Nasal Spray (Opvee) for Reversal of Opioid Overdose

(2023) · ˜The œmedical letter on drugs and therapeutics/˜The œmedical letter · doi:10.58347/tml.2023.1687b

In vivo characterization of the opioid antagonist nalmefene in mice

Osborn, M. D., Lowery, J. J., Skorput, A. G. J., et al. (2010) · Life Sciences · doi:10.1016/j.lfs.2010.02.013 · Cited by 25 · see citing works

Second generation opioidergic compounds: clinical data

Sinclair, J. D. (2006) · Birkhäuser-Verlag eBooks · doi:10.1007/3-7643-7305-9_12 · Cited by 1 · see citing works

Use of a narcotic antagonist (nalmefene) to suppress self-mutilative behavior in a stallion

Dodman, N. H., Shuster, L., Court, M. H., et al. (1988) · Journal of the American Veterinary Medical Association · doi:10.2460/javma.1988.192.11.1585 · Cited by 31 · see citing works

Nalmefene: A Long-Acting Opioid Antagonist. Clinical Applications In Emergency Medicine

Wang, D. S., Sternbach, G. L., & Varón, J. (1998) · Journal of Emergency Medicine · doi:10.1016/s0736-4679(98)00019-5 · Cited by 51 · see citing works